February 11, 2009 8:17 PM
- Text
New Treatment For Skin Cancer
(AP)
A non-surgical treatment for basal cell skin cancer results in better cosmetic results but might be less effective than surgery at preventing the disease from returning, a study found.
The treatment is called photodynamic therapy and uses skin cream and concentrated light to activate the cream, which kills cancer cells. It is used in Europe, Australia and New Zealand, but a Food and Drug Administration advisory committee last year recommended against U.S. approval.
Basal cell skin cancer, often caused by overexposure to sunlight, is diagnosed in about 2 million people worldwide each year, making it among the most common cancers. It is also among the most curable. Surgical removal is generally the preferred treatment, but since basal cell cancers typically appear on or around the face, some patients worry about scarring.
The new study, published in Monday's Archives of Dermatology, involved 101 patients who received either surgery or two treatment sessions a week apart with Metvix, also known as methyl aminolevulinate cream.
Two years later, cosmetic results from the Metvix treatment got higher marks from patients and doctors, but five cancers treated with Metvix had recurred, compared with one among the surgery patients.
The FDA has approved similar therapy for precancerous skin lesions. But an FDA advisory committee recommended against approval of Metvix after deciding the benefits did not outweigh the risks of recurrence.
PhotoCure of Oslo, Norway, which makes Metvix and funded the study, is challenging the committee's findings. The company has "shown efficacy and safety ... everything that is required" for U.S. approval, said Dr. Vidar Hansson, PhotoCure president.
Hansson said the true cancer-recurrence rates for the two treatments might be closer to each other than the study indicates, because data on several patients in both groups was missing.
Study author Dr. Lesley Rhodes of Hope Hospital in Salford, England, and colleagues said that Metvix might still be preferable for patients who prefer an "excellent cosmetic outcome" over surgery.
Hansson said Metvix treatment can be repeated if cancer recurs.
CBS News Anchor Dan Rather returned to the air Monday after taking time off to have some possibly cancerous basal cells removed from his nose.
"I thank you for your concern and urge you to get a skin cancer exam,'' Rather told viewers.
By Lindsey Tanner
The treatment is called photodynamic therapy and uses skin cream and concentrated light to activate the cream, which kills cancer cells. It is used in Europe, Australia and New Zealand, but a Food and Drug Administration advisory committee last year recommended against U.S. approval.
Basal cell skin cancer, often caused by overexposure to sunlight, is diagnosed in about 2 million people worldwide each year, making it among the most common cancers. It is also among the most curable. Surgical removal is generally the preferred treatment, but since basal cell cancers typically appear on or around the face, some patients worry about scarring.
The new study, published in Monday's Archives of Dermatology, involved 101 patients who received either surgery or two treatment sessions a week apart with Metvix, also known as methyl aminolevulinate cream.
Two years later, cosmetic results from the Metvix treatment got higher marks from patients and doctors, but five cancers treated with Metvix had recurred, compared with one among the surgery patients.
The FDA has approved similar therapy for precancerous skin lesions. But an FDA advisory committee recommended against approval of Metvix after deciding the benefits did not outweigh the risks of recurrence.
PhotoCure of Oslo, Norway, which makes Metvix and funded the study, is challenging the committee's findings. The company has "shown efficacy and safety ... everything that is required" for U.S. approval, said Dr. Vidar Hansson, PhotoCure president.
Hansson said the true cancer-recurrence rates for the two treatments might be closer to each other than the study indicates, because data on several patients in both groups was missing.
Study author Dr. Lesley Rhodes of Hope Hospital in Salford, England, and colleagues said that Metvix might still be preferable for patients who prefer an "excellent cosmetic outcome" over surgery.
Hansson said Metvix treatment can be repeated if cancer recurs.
CBS News Anchor Dan Rather returned to the air Monday after taking time off to have some possibly cancerous basal cells removed from his nose.
"I thank you for your concern and urge you to get a skin cancer exam,'' Rather told viewers.
By Lindsey Tanner
Popular Now in Health
- Cancer drug reverses Alzheimer's in mice: Study
- Marijuana-smoking motorists twice as likely to crash
- 4.5 million Americans over 50 have artificial knees
- Skin cancer self-exam: What to look for (PHOTOS)
- Norovirus outbreak hits Rider University in N.J
- America's pets also have an obesity epidemic
- Things You Didn't Know About Your Penis
- America's sodium problem: Not from salty snacks?
- PICTURES: 15 Shocking Sexual Fetishes
- Caffeine inhalers - the next club drug?
- Let's Move! campaign turns 2 today: Is it working?
- Chinese mom gives birth to 15-pound baby
- John Dye Dies: What Killed "Angel" Star?
- Woman spotlights uterus didelphys on talk show
- Christina Hendricks: Too Big for Hollywood?
- 8 Tips For Losing Weight After Pregnancy
- Measles patient at Super Bowl prompts health alert
Latest CBS News Headlines
on Facebook
on CBS News
- Holliday leads 76ers past short-handed Cavs 99-84
- Nuggets upend Pacers 113-109
- Griffin, Paul lead Clippers over Bobcats 111-86
- Whitney Houston died in Beverly Hills hotel room
on Facebook
- Adele sings a cappella for Anderson Cooper
- Occupy protestors kicked out of CPAC
- CPAC: Will Sarah Palin spring a surprise?
- Beyonce and Jay-Z post first photos of Blue Ivy Carter
on CBS News






